BriaCell Therapeutics Corp. said it will consolidate a larger number of shares than previously communicated.
The Canadian biotechnology will undertake a reverse stock split of its shares at a ratio of 1-for-300 as opposed to 1-for-100 previously.
The move will help the immuno-oncology company apply for a listing on a recognized U.S. stock exchange. BriaCell's shares are listed on Canada's TSX Venture Exchange and the OTCQB in the U.S.
